CAS NO: | 79350-37-1 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
Cas No. | 79350-37-1 |
别名 | 头孢克肟; FR-17027; FK-027; CL-284635 |
化学名 | (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-[carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
Canonical SMILES | [H][C@@]1([C@@H]2NC(/C(C3=CSC(N)=N3)=N\OCC(O)=O)=O)N(C(C(O)=O)=C(C=C)CS1)C2=O |
分子式 | C16H15N5O7S2 |
分子量 | 453.4 |
溶解度 | ≤5mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide |
储存条件 | Store at 2-8℃, protect from light |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | MIC: from<0.025 to 25 μg/ml for E. coli, K. pneumoniae, and H. influenzae Cefixime is a third generation cephalosporin antibiotic. The cephalosporins, a class of β-lactam antibiotics, are originally derived from the fungus Acremonium. In vitro: Previous study found that cefixime was more active than cephalexin, cefaclor, and amoxicillin against various gram-negative bacteria. Cefixime was also significantly more active than tested reference drugs against clinical isolates of Klebsiella pneumoniae, Escherichia coli, indole-positive and -negative Proteus species, Providencia species, and Neisseria gonorrhoeae. Moreover, cefixime was active against strains of K. pneumoniae, E. coli, as well as Proteus mirabilis resistant to the reference agents [1]. In vivo: The therapeutic activities of cefixime in mice infected with gram-negative bacilli were found to be far superior to the activities of cephalexin, cefaclor, and amoxicillin, but they were inferior to the activities against infection with Staphylococcus aureus [1]. Clinical trial: Previous study showed that the clinical success was observed in 94% of cefixime-treated patients. At the end of treatment, the overall eradication rate in the cefixime treatment group was 92% and ranged from 76% (cefaclor) to 98% (cefuroxime axetil) in the comparator treatment groups [2]. References: |